WebMay 31, 2024 · About Trillium Therapeutics Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). WebAug 23, 2024 · Shares of Trillium Therapeutics Inc. TRIL, nearly tripled in premarket trading Monday, skyrocketing 189.3%, after the immuno-oncology company announced an …
Pfizer Agrees to Buy Cancer Biotech Trillium Therapeutics at a …
WebJul 7, 2024 · Find the latest Trillium Therapeutics Inc., TRIL stock market data. Get a full understanding of how Trillium Therapeutics Inc. is performing with stock quotes and prices, as well as real-time news ... WebDate: Time: Source: Headline: Symbol: Company: 04/11/2024: 7:00AM: PR Newswire (Canada) Silver Valley Metals Announces Exploration Results from the Ranger-Wyoming Complex at its Ranger-Page ... put an app on my phone
Trillium Therapeutics: A Frazier Healthcare Partners Portfolio …
WebAug 23, 2024 · Get all latest & breaking news on Trillium Therapeutics. Watch videos, top stories and articles on Trillium Therapeutics at moneycontrol.com. WebOn 17 November 2024, Pfizer announced the acquisition of Trillium Therapeutics, which is a clinical-stage immuno-oncology company that focuses on developing innovative therapies for cancer treatment. This acquisition is expected to enhance Pfizer's oncology portfolio and strengthen its position in the controlled release drug delivery market. WebTORONTO, ONTARIO--(Marketwired - Nov. 15, 2024) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has entered into subscription agreements for the sale of 1,950,000 common shares and 400,000 Series II … seeds park hills mo